leu2 his3 LYS2::lexA-HIS3 URA3::lexA-lacZ; provided by S. Hollenberg and J. Cooper) generating the N-Vav L40 strain. Expression of the fusion protein was confirmed by immunoblot analysis of yeast total cell lysates with anti-LexA serum (data not shown). A lymphocyte cDNA library fused to the GAL4 activation domain in the pACT vector (Clontech) was transformed into the N-Vav L40 strain, and 10 6 transformants were screened for interactors as described previously (40) . Yeast plasmid DNA was isolated from His ϩ ␤-Gal ϩ colonies, rescued into Escherichia coli HB101, retransformed with appropriate control baits into L40, and assayed for ␤-galactosidase (␤-Gal) activity and growth on Dropout medium with complete supplement lacking Trp, Leu, Ura, Lys, and His (Bio101). For the delineation of binding domains in the two-hybrid assay, the respective Vav and ENX-1 fragments were obtained by PCR, cloned into fusion protein vectors pBTM116 and pVP16, respectively, sequentially transformed into the L40 strain, and monitored for reporter gene activity.
DNA sequence analysis and cDNA library screen. Vav-specific cDNA clones derived from the two-hybrid screen were subjected to automated sequencing analysis by the dideoxynucleotide chain termination method. Nonredundant nucleotide sequence databases (GenBank and EMBL) were searched for homologous sequences by using the Basic Local Alignment Search Tool, which employs the statistical methods of Karlin and Altschul (20, 21) , as a search algorithm. To obtain 5Ј-terminal ENX-1 sequences, the ENX-1 cDNA obtained from the two-hybrid analysis was used to screen a human ZR75 cDNA phage library by standard protocols (32) . 5Ј sequences isolated from that screen were fused by conventional DNA cloning techniques to the ENX-1 two-hybrid clone.
Cell lines and cell lysis. Jurkat and HEL cells were maintained in RPMI medium supplemented with 2 mM glutamine and 10% fetal bovine serum. Human embryonic kidney fibroblasts of the 293 cell line were maintained in Dulbecco modified Eagle medium supplemented with 2 mM glutamine and 10% fetal bovine serum. Total cellular lysates were obtained by incubation with RIPA buffer (1ϫ phosphate-buffered saline, 1% Nonidet P-40 , 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS] ). Subcellular fractionation of cells by sequential lysis with NP-40 and RIPA buffer was done as described previously (37) .
GST fusion protein binding assays. Glutathione S-transferase (GST) fusion proteins were obtained by cloning the N-terminal domain of vav (residues 1 to 172) and the ENX-1 two-hybrid clone (⌬ENX-1; residues 67 to 613) into pGEX2T (Pharmacia). Expression, purification, and binding assays were done essentially as previously described (18) .
Expression of Vav and ENX-1 in 293 embryonic kidney fibroblasts. Vav and either truncated ⌬ENX-1 or full-length ENX-1 were cloned in the cytomegalovirus promoter-based pRK5 expression vector, transfected in 293 cells by the calcium phosphate precipitation method, and lysed 36 h after transfection in RIPA buffer (18) .
Antibodies, Western blotting (immunoblotting), and immunoprecipitation. Antibodies against ENX-1 were raised by immunizing rabbits with an ENX-1 C-terminal peptide (residues 600 to 613) coupled to keyhole limpet hemocyanin. After the initial immunization, rabbits were given booster injections four times at 3-week intervals, and control blood samples and final blood samples were taken after the last immunization. For immunoprecipitation, 3 g of monoclonal antihemaglutinin (HA) antibody 12CA5, 10 l of anti-ENX-1 serum, or 10 l of preimmune serum was bound to 40 l of protein A-Sepharose suspension and incubated with the respective cell lysates for at least 3 h at 4ЊC. Beads were washed extensively with HNTG buffer (10 mM HEPES [N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid] [pH 7.5], 150 mM NaCl, 0.1% Triton X-100, 10% glycerol), and bound protein was eluted with SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer.
For Western blot analysis, SDS-PAGE-separated proteins were blotted onto a nitrocellulose membrane and incubated with the respective antibody. Bound antibodies were visualized by using the ECL system (Amersham). The antibodies used for Western blot analysis included an anti-Vav monoclonal antibody obtained from Upstate Biotechnology Inc., used at a 1:1,000 dilution, and the anti-HA antibody 12CA5, used at a 1:1,000 dilution.
The depletion of ENX-1 antiserum with GST-⌬ENX-1 protein or GST control protein was performed by incubating 100 l of antiserum overnight at 4ЊC with approximately 100 g of the respective proteins, which were immobilized on glutathione-Sepharose beads. After incubation, the beads were spun down and the supernatant was used for immunoprecipitation analysis.
Northern (RNA) blot analysis. A human multiple-cell-line Northern blot was purchased from Clontech and probed as recommended by the manufacturer with a [␥-
32 P]ATP-labeled 1,700-bp ENX-1 fragment at high stringency. Nucleotide sequence accession number. The GenBank accession number for ENX-1 is U52965.
RESULTS
Cloning of ENX-1. In order to identify Vav-interacting proteins, we employed the yeast two-hybrid system (10, 40) with the N-terminal domain (N-Vav; amino acids 1 to 172) as a bait to screen a human lymphocyte cDNA library. Of 10 6 clones screened, we isolated one, N8, with a 2-kb cDNA insert that specifically interacted with Vav, as summarized in Table 1 .
Sequence similarity searches using the Basic Local Alignment Search Tool search algorithm (20, 21) revealed a high degree of similarity between this clone (Fig. 1A) and the Drosophila Enhancer of zeste [E(z)] gene (Fig. 1B) , which is involved in transcriptional regulation of homeobox (Hox) gene expression (19) . The remarkable conservation of several sequence features of E(z) in the novel human sequence suggested that it is the human homolog of the Drosophila gene (Fig. 1B) . We therefore termed the N8-encoded protein ENX-1.
Sequence comparison between E(z) and ENX-1 suggested that the clone which we isolated from the two-hybrid library did not contain a complete 5Ј end. Missing 5Ј sequences encoding an additional 67 N-terminal amino acids were isolated from a ZR75 human cDNA library. The full-length ENX-1 cDNA has a size of 2.7 kb and contains an open reading frame for a 613-amino-acid protein (Fig. 1A) . Several short, partially overlapping sequences which are highly homologous but not identical to ENX-1 (Fig. 1C) and localized on chromosome 17q21 (4, 15, 28) were identified in the GenBank database. The homologies of these sequences to that of Drosophila E(z) had already been noted by others in the search for the adjacent BRCA1 gene (4, 15, 28) . Because of its sequence homology with ENX-1, we designated this gene on chromosome 17q21 ENX-2 (Fig. 1C) . The transcript size of this gene, approximately 5 kb, in comparison with the 2.7-kb ENX-1 mRNA suggests a relationship with a second, larger Drosophila E(z)-related transcript already identified (19) and therefore the existence of an E(z)-and ENX-1-related gene family in invertebrates and vertebrates.
Structural motifs of ENX-1. Sequence comparison of human ENX-1 and Drosophila E(z) revealed the presence of three highly conserved sequence stretches in their N-terminal regions, which we termed boxes 1, 2, and 3 ( Fig. 1B) . Protein database searches did not reveal significant similarities between these sequences and those of other proteins. Between box 1 and box 2 of ENX-1, highly acidic sequence stretches, similar to those identified in Drosophila E(z) within the same region (19) , are present. Downstream from a nuclear localization consensus sequence in E(z) and ENX-1, 17 cysteine residues are perfectly conserved in both proteins. Within this region, three sequence units, C-X 6 -C-X 3 -C-X-C (X ϭ any residue), are repeated; one of them is inverted. This domain shows no homology to other structurally well-defined Cys-rich domains (19) , such as the Zn finger (3), LIM motif (33), PHD domain (1), B box (31), or RING finger (14) . As most intracellular, metal-coordinating Cys-rich domains are characterized by the spacing of Cys residues by at least 2 amino acids (C-X 2 -C) (13), the appearance of multiple cysteine residues in ENX-1 and E(z) separated by only 1 amino acid represents a novel motif, which, when occurring as a cluster, we propose to designate the CXC domain. On the basis of its high degree of conservation during evolution, we expect this domain to fulfill an important function and to occur in other proteins, although initial database searches have not yet revealed any significant matches.
At its most C-terminal end, ENX-1 carries a highly conserved SET domain (36) of unknown function, which was recently found to be present in proteins from yeasts, plants, nematodes, mice, and humans (18a).
Interacting domains of Vav and ENX-1. Since both Vav and ENX-1 contain several defined sequence motifs, we next sought to determine which of these motifs are responsible for their interaction. For this purpose, we cloned several parts of Vav and ENX-1 into yeast two-hybrid expression vectors and determined the interaction by monitoring the growth of yeast transformants on medium lacking His and by assaying ␤-Gal activity. Both assays yielded similar results, demonstrating that a short (49-amino-acid) stretch of Vav 3Ј adjacent to sequences deleted in oncogenic Vav is sufficient to bind ENX-1 protein (Fig. 2) . As originally observed by Katzav et al. (22, 23) , this domain of Vav contains a Leu-zipper-like motif. Replacement of the leucine by a phenylalanine, however, had no effect on ENX-1 binding to Vav (data not shown).
We found both the CXC domain and the SET domain of ENX-1 to be dispensable for ENX-1 binding to Vav, since the more N-terminally located sequence stretch of ENX-1 (amino acids 67 to 318), which contains the highly conserved box 2 and box 3 sequence stretches (Fig. 1B) , readily bound Vav in the two-hybrid assay (Fig. 2) .
Binding of Vav to ENX-1 in vitro. To confirm the interaction results obtained in the two-hybrid assay, we performed in vitro solution binding assays. For this purpose, the N-terminal domain of Vav was expressed and purified as a GST fusion protein (GST-N-Vav), immobilized on a matrix, and examined for its capacity to bind ENX-1 from cellular lysates. To allow the detection of ENX-1 protein by Western blot analysis, we tagged the initially isolated ENX-1 two-hybrid clone ⌬ENX-1 (lacking 66 N-terminal amino acids) with a C-terminal HA epitope, transfected in 293 embryonic fibroblasts, and confirmed expression by immunoblotting total cellular lysates with monoclonal anti-HA antibody (Fig. 3A, first two lanes) . After incubating 293 cell lysates expressing ⌬ENX-1 with GST-NVav and a control affinity matrix, we found ENX-1 to specifically associate with the Vav affinity matrix by immunoblot analysis with monoclonal anti-HA antibody (Fig. 3A) .
In the reverse experiment, we expressed ⌬ENX-1 as a GST (Fig. 3B) . Using an independent assay system, we were thus able to confirm the results obtained in the two-hybrid assay, demonstrating the capability of Vav and ENX-1 to interact both in vitro and in yeast cells.
ENX-1 gene expression in human cells.
To begin investigating the biological role of ENX-1, we examined its expression patterns in various cell lines. Northern blot analysis of mRNA detected a 2.7-kb message widely expressed in hematopoietic and nonhematopoietic cells (Fig. 4A and data not shown) . VOL. 16, 1996 Vav-ENX- S]methionine and immunoprecipitating cellular lysates with the ENX-1 antiserum. Again, an 80-kDa band was detected by the specific serum, while preimmune serum did not precipitate this protein (Fig. 4D) .
A 105-kDa protein was consistently coprecipitated with the anti-ENX-1 serum from both hematopoietic cell lysates and nonhematopoietic cell lysates (Fig. 4D and data not shown) . This protein might represent either an associated protein or the ENX-2 gene product from chromosome 17q21.
Coimmunoprecipitation of Vav with ENX-1 in vivo.
In order to examine complex formation of Vav with ENX-1 in intact mammalian cells, we first coexpressed both proteins in 293 embryonic fibroblasts, which do not contain endogenous Vav protein. Proteins from 293 cell lysates expressing either ENX-1 alone, Vav alone, or ENX-1 together with Vav were immunoprecipitated with monoclonal antibodies directed against HA epitope-tagged ENX-1 and immunoprobed with a monoclonal antibody directed against the Vav protein. As shown in Fig.  5A , under these conditions Vav coprecipitated with ENX-1, the expression of which was confirmed independently by reprobing the nitrocellulose membrane with epitope-directed anti-HA antibody (Fig. 5B) .
Next, we examined whether a complex of endogenous Vav and ENX-1 proteins could also be detected in hematopoietic cell lines. As suggested by the function of its Drosophila homolog and the presence of a nuclear localization sequence, ENX-1 presumably localizes to the nucleus. Similarly, Vav contains such a signal sequence (22, 23) to be present in the nucleus (9, 26) . To distinguish between nuclear or cytosolic localization of an ENX-1-Vav complex, we prepared respective fractions from Jurkat T-lymphoblastic and HEL megakaryocytic cell lines by sequential extraction of cells with NP-40 and RIPA buffer, as described previously (37) . Equal amounts of protein from these subcellular extracts were precleared with preimmune serum and then precipitated with either preimmune serum or specific anti-ENX-1 serum. As shown in Fig. 6A , in nuclear extracts of both Jurkat and HEL cells, the 80-kDa ENX-1 protein was detected. By probing the anti-ENX-1 immunoprecipitates with monoclonal antibody, Vav was also detected in the nuclear fractions of Jurkat and HEL cells, indicating association with ENX-1 (Fig. 6B) . To a much lesser extent, Vav was also found in the cytoplasmic fractions of HEL cells (Fig. 6B) .
To confirm the specificity of complex formation between ENX-1 and Vav, we precipitated RIPA-lysed Jurkat cells with either anti-ENX-1 serum, preimmune serum, or anti-ENX-1 serum depleted of specific ENX-1 antibodies by preincubation with a GST-ENX-1 fusion protein. Figure 6C shows that Vav protein was detected only in specific anti-ENX-1 immunoprecipitates.
In summary, our results provide evidence for specific in vivo complex formation between the Vav protein and the putative transcriptional regulator ENX-1 in hematopoietic cells.
DISCUSSION
We report here the identification and characterization of the Vav-associated protein ENX-1, a putative member of the Polycomb group (Pc-G) of genes, which are involved in regulating the expression of Hox genes in both Drosophila melanogaster and vertebrates (reviewed in references 27 and 34). Products of the Pc-G genes, such as the Polycomb, Polyhomeotic, and E(z) proteins, are thought to form multimeric protein complexes on chromatin that bind to specific Hox gene-regulatory regions, leading to the repression of Hox gene transcription (12, 27, 30, 34) . The Drosophila E(z) protein plays an important role in the formation of these repression complexes, since disruption of this gene leads to the dissociation of complexes of the Pc-G gene products from chromatin (30) . The well characterized effects of mutations in Drosophila Pc-G members, including E(z), on Hox gene expression (19) and the significant sequence conservation between Drosophila E(z) and the human ENX-1 protein suggest that ENX-1 plays a similarly important role in regulating Hox gene expression in vertebrates.
Studies of another vertebrate Pc-G gene, the mouse posterior VOL. 16, 1996 Vav-ENX- (24, 25) . For example, in quiescent primary T lymphocytes, the HoxB cluster genes are not expressed but become coordinatively induced by the activation of T-cell proliferation (8) . Since artificial downregulation of these Hox genes inhibits T-cell proliferation, an important role for Hox gene expression in the proliferation of hematopoietic cells can be assumed (8) .
Similarly, recent studies of the Vav protein have demonstrated its involvement in B-and T-cell proliferation and activation (11, 35, 42) . Our discovery of complex formation between the signal-transducing protein Vav and ENX-1, a putative regulator of Hox gene expression, leads us to suggest a significant function for this interaction in coordinated regulation of Hox gene expression in the hematopoietic system.
Developmental-expression analysis of the murine homolog of ENX-1 revealed it to be predominantly expressed in hematopoietic organs of the mouse embryo (18a), further supporting the notion of a specific involvement of ENX-1 in hematopoiesis. Nevertheless, nonhematopoietic expression of ENX-1 was also found (Fig. 4A and data not shown) , implying that ENX-1 also fulfills a function outside the hematopoietic system, which might in turn be regulated by some other cell-typespecific signal regulator analogous to Vav. ENX-1 might thus represent a protein that by association with tissue-specific regulatory proteins is able to control cell-type-specific expression of Hox genes.
Both Vav and ENX-1 contain nuclear localization sequences (23) (Fig. 1) . In agreement with this, we found ENX-1 predominantly localized to the nucleus, while we detected both cytosolic and nuclear pools of Vav protein (data not shown). Clevenger et al. (9) have recently reported the translocation of Vav to the nucleus upon the induction of T-cell proliferation by prolactin. As we could not find stimuli, such as tyrosine phosphorylation of Vav, to regulate its association with ENX-1, the induction of Vav-ENX-1 complex formation may be controlled by changes in subcellular localization or alternatively by as-yet-uncharacterized stimuli.
The in vitro guanine nucleotide exchange factor activity of Vav for small GTP-binding proteins and its association with regulators of the Ras signaling pathway (16, 29, 41) and transcriptional regulators (18) (this study) suggest that Vav is a multifunctional, signal-modulating protein with functions in the cytosolic and nuclear compartments. This hypothesis is supported by the recent observation that the induction of Tcell proliferation by prolactin has a biphasic effect on Vav activity. The in vitro exchange factor activity of Vav is first temporarily activated, and then there is the translocation of Vav to the nucleus (9) , where upon interaction with ENX-1 it may take part in gene-regulatory events.
